| 23.68 -0.12 (-0.5%) | 11-02 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 28.61 | 1-year : | 33.42 |
| Resists | First : | 24.5 | Second : | 28.61 |
| Pivot price | 23.13  |
|||
| Supports | First : | 22.6 | Second : | 21.43 |
| MAs | MA(5) : | 23.54 |
MA(20) : | 22.85 |
| MA(100) : | 28.43 |
MA(250) : | 35.78 |
|
| MACD | MACD : | 0 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 81.4 |
D(3) : | 78.5 |
| RSI | RSI(14): 55.4 |
|||
| 52-week | High : | 50.78 | Low : | 21.43 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ COLL ] has closed below upper band by 25.7%. Bollinger Bands are 53.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 30 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 24.53 - 24.66 | 24.66 - 24.77 |
| Low: | 23.36 - 23.5 | 23.5 - 23.63 |
| Close: | 23.56 - 23.81 | 23.81 - 24.02 |
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
Mon, 02 Nov 2026
Collegium Pharmaceutical (COLL) Repositioning: Shifting Focus from Pain Management to ADHD - Yahoo Finance
Sat, 31 Oct 2026
Collegium Pharmaceutical, Inc. (COLL) Stock Price, News, Quote & History - Yahoo! Finance Canada
Fri, 30 Oct 2026
Collegium Pharmaceutical, Inc. (COLL) Seasonal Returns Chart - Yahoo! Finance Canada
Fri, 30 Oct 2026
Collegium Pharmaceutical, Inc. (COLL) Seasonal returns chart - Yahoo Finance UK
Thu, 29 Oct 2026
Collegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across Massachusetts - Yahoo Finance
Thu, 29 Oct 2026
Collegium Pharmaceutical, Inc. (COLL) Stock forecasts - Yahoo Finance Singapore
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 33 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 129.9 (%) |
| Shares Short | 5,520 (K) |
| Shares Short P.Month | 6,060 (K) |
| EPS | 1.26 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.6 |
| Profit Margin | 5.9 % |
| Operating Margin | 5.6 % |
| Return on Assets (ttm) | 5.7 % |
| Return on Equity (ttm) | 17.6 % |
| Qtrly Rev. Growth | 6.3 % |
| Gross Profit (p.s.) | 22.2 |
| Sales Per Share | 24.82 |
| EBITDA (p.s.) | 12.44 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 330 (M) |
| Levered Free Cash Flow | 324 (M) |
| PE Ratio | 18.64 |
| PEG Ratio | 0.6 |
| Price to Book value | 2.46 |
| Price to Sales | 0.95 |
| Price to Cash Flow | 2.33 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|